China Biotech Services (08037) signed a memorandum of understanding with Stella Pharma Corporation.

According to the Zhixun Finance APP, China Biotech Services (08037) announced that on May 8, 2025, the Company, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. (Pengbo Hainan), and Stella Pharma Corporation (Stella Pharma) (collectively referred to as the "parties to the agreement") have entered into a Memorandum of Understanding (MOU) regarding further cooperation on the sales and production of STEBORONINE (a drug used for Boron Neutron Capture Therapy (BNCT) targeting unresectable, locally advanced, or locally recurrent head and neck cancer) (Boron Neutron Capture Therapy drug) in the People's Republic of China (China, excluding Hong Kong, Macau, and Taiwan) as an important part of the ongoing cooperation between the parties.